$Recursion Pharmaceuticals(RXRX.US)To be honest, I really don't understand this company. There are many AI + pharmaceutical concept companies, but they are all lukewarm. The truly effective R&D still relies on frontline researchers, and the most expensive stage is from candidate drugs to human trials. Currently, AI is still stuck in the stage of screening candidate drugs? I think so. In this case, the advantage of AI over humans is that it can screen enough candidate drugs, but these drugs must first undergo animal and human trials before they can be ultimately applied to disease treatment. This step is the most time-consuming and costly. If AI can optimize this step at some point, I think this type of stock will be worth buying. Otherwise, the advantage of these companies is that they use AI to screen potential drugs and then sell them directly to big companies, or they produce positive Phase 1 results and sell them. Those are not much different from traditional pharmaceutical companies.